85 related articles for article (PubMed ID: 25541464)
1. Yeast as a model system to screen purine derivatives against human CDK1 and CDK2 kinases.
Mayi T; Facca C; Anne S; Vernis L; Huang ME; Legraverend M; Faye G
J Biotechnol; 2015 Feb; 195():30-6. PubMed ID: 25541464
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor.
Davies TG; Bentley J; Arris CE; Boyle FT; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Hardcastle IR; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Wang L; Whitfield HJ
Nat Struct Biol; 2002 Oct; 9(10):745-9. PubMed ID: 12244298
[TBL] [Abstract][Full Text] [Related]
3. Human Cdk2 is a functional homolog of budding yeast Ime2, the meiosis-specific Cdk-like kinase.
Szwarcwort-Cohen M; Kasulin-Boneh Z; Sagee S; Kassir Y
Cell Cycle; 2009 Feb; 8(4):647-54. PubMed ID: 19197163
[TBL] [Abstract][Full Text] [Related]
4. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
5. Synthesis of 6-(het) ary Xylocydine analogues and evaluating their inhibitory activities of CDK1 and CDK2 in vitro.
Xiao C; Sun C; Han W; Pan F; Dan Z; Li Y; Song ZG; Jin YH
Bioorg Med Chem; 2011 Dec; 19(23):7100-10. PubMed ID: 22036212
[TBL] [Abstract][Full Text] [Related]
6. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
7. N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
Hardcastle IR; Arris CE; Bentley J; Boyle FT; Chen Y; Curtin NJ; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Menyerol J; Mesguiche V; Newell DR; Noble ME; Pratt DJ; Wang LZ; Whitfield HJ
J Med Chem; 2004 Jul; 47(15):3710-22. PubMed ID: 15239650
[TBL] [Abstract][Full Text] [Related]
8. Discovery and evaluation of dual CDK1 and CDK2 inhibitors.
Payton M; Chung G; Yakowec P; Wong A; Powers D; Xiong L; Zhang N; Leal J; Bush TL; Santora V; Askew B; Tasker A; Radinsky R; Kendall R; Coats S
Cancer Res; 2006 Apr; 66(8):4299-308. PubMed ID: 16618755
[TBL] [Abstract][Full Text] [Related]
9. Chemical and biological profile of dual Cdk1 and Cdk2 inhibitors.
Ruetz S; Fabbro D; Zimmermann J; Meyer T; Gray N
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):1-14. PubMed ID: 12678910
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
11. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
12. Molecular models of cyclin-dependent kinase 1 complexed with inhibitors.
Canduri F; Uchoa HB; de Azevedo WF
Biochem Biophys Res Commun; 2004 Nov; 324(2):661-6. PubMed ID: 15474478
[TBL] [Abstract][Full Text] [Related]
13. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
15. Critical reanalysis of the methods that discriminate the activity of CDK2 from CDK1.
Sakurikar N; Eastman A
Cell Cycle; 2016 May; 15(9):1184-8. PubMed ID: 26986210
[TBL] [Abstract][Full Text] [Related]
16. Purine analogs as CDK enzyme inhibitory agents: a survey and QSAR analysis.
Lee AD; Ren S; Lien EJ
Prog Drug Res; 2001; 56():155-93. PubMed ID: 11417113
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of potent CDK1 inhibitors derived from olomoucine.
Furet P; Zimmermann J; Capraro HG; Meyer T; Imbach P
J Comput Aided Mol Des; 2000 Jul; 14(5):403-9. PubMed ID: 10896313
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
19. Cdk1, but not Cdk2, is the sole Cdk that is essential and sufficient to drive resumption of meiosis in mouse oocytes.
Adhikari D; Zheng W; Shen Y; Gorre N; Ning Y; Halet G; Kaldis P; Liu K
Hum Mol Genet; 2012 Jun; 21(11):2476-84. PubMed ID: 22367880
[TBL] [Abstract][Full Text] [Related]
20. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors.
Gray NS; Wodicka L; Thunnissen AM; Norman TC; Kwon S; Espinoza FH; Morgan DO; Barnes G; LeClerc S; Meijer L; Kim SH; Lockhart DJ; Schultz PG
Science; 1998 Jul; 281(5376):533-8. PubMed ID: 9677190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
